MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA
References (16)
- et al.
One hundred patients with acute leukaemia treated by chemotherapy, total body irradiation and allogeneic bone marrow transplantation
Blood
(1977) - et al.
The place of bone marrow transplantation in acute myelogenous leukaemia
Lancet
(1980) - et al.
Cyclosporin A to prevent graft-versus-host disease after allogeneic bone marrow transplantation
Lancet
(1980) - et al.
Marrow transplantation for acute nonlymphoblastic leukaemia in first remission
N Engl J Med
(1979) - et al.
Bone marrow ablation and allogeneic marrow transplantation in acute leukaemia
N Engl J Med
(1980) - et al.
Marrow transplantation for acute nonlymphoblastic leukaemia in first remission
Blut
(1980) A prospective controlled trial of bone marrow transplantation vs. chemotherapy in acute myelogenous leukaemia
Blood
(1981)
Cited by (214)
Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China
2023, Blood ReviewsCitation Excerpt :Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative option for treating hematologic malignant and non-malignant conditions. Initially, allo-HSCT could only be performed between human leukocyte antigen (HLA)-matched donors and recipients because a formidable HLA barrier led to high incidences of graft failure (GF) and graft versus host disease (GvHD) [1,2]. In recent decades, haploidentical donor stem cell transplantation (haplo-SCT), especially non T cell depletion in vitro strategies, including the granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG)-based Beijing protocol and the posttransplantation cyclophosphamide (PT-Cy)-based Baltimore protocol, have made great advances.
Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective
2022, Transplantation and Cellular TherapyCitation Excerpt :As larger numbers of patients are treated with CD19 CAR T for B-ALL, leveraging cellular therapy registries may provide insight and predictive modeling that could inform decisions on whether to proceed to consolidative allo-HCT after CD19 CAR T cell therapy. The pioneering work in both allo-HCT and auto-HCT, although initially met with skepticism and frustration, eventually demonstrated the curative potential of these modalities in advanced, otherwise fatal hematologic malignancies [21,69-73]. By circumventing the dose-limiting toxicity of myeloablation, these therapies greatly increased the therapeutic windows for cytotoxic chemotherapy regimens and, in the case of allo-HCT, unlocked the immunotherapeutic benefit of the donor immune system.
Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome
2022, Transplantation and Cellular TherapyGraft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study
2021, Transplantation and Cellular TherapyImmune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients
2021, Transplantation and Cellular Therapy